Retzius-Sparing Prostatectomy: Is It Really a Game-Changer?

RS-RARP is a surgical technique used in prostate cancer treatment that aims to improve urinary continence recovery after surgery. Unlike standard RARP, the RS-RARP approach preserves the Retzius space, the area between the pubic bone and the bladder. This preservation is believed to lead to faster continence recovery because it keeps the bladder's natural support structures intact, avoids bladder dropping, maintains the endopelvic fascia and puboprostatic ligaments, and minimizes disruption to the tissues supporting the urethra. Standard RARP often disturbs the Retzius space, potentially leading to a longer recovery period for urinary control.

Preserving the Retzius space during RS-RARP contributes to better urinary continence because it maintains several crucial anatomical structures. These include keeping the bladder's natural support structures, preventing the bladder from dropping, maintaining the endopelvic fascia and puboprostatic ligaments (critical for urethral support), and minimizing disruption to the tissues that support the urethra. By keeping these structures intact, RS-RARP reduces bladder neck descent, which is associated with improved continence.

Several studies have shown promising early continence rates with RS-RARP. One study indicated that continence rates (defined as no pad or safety pad use) reached 90% to 96% at one week and one year post-surgery, respectively. Another study reported a 70% continence rate at one month after RS-RARP. While the specific continence rates for standard RARP are not detailed in the provided context, the key advantage of RS-RARP lies in its potential for faster and improved continence recovery compared to standard techniques.

While the primary benefit of RS-RARP is enhanced early urinary continence recovery, patients should also consider oncological safety and long-term outcomes. It's crucial to discuss these aspects with their surgeons to ensure that the surgical approach chosen is the most appropriate for their individual circumstances. The long-term data is still developing. Comprehensive understanding of the cancer's specifics, overall health, and potential risks and benefits is essential.

It is important for patients to have thorough discussions with their surgeons regarding RS-RARP because the decision about prostate cancer surgery is highly individual. These discussions should cover several key aspects. First, patients should understand the potential benefits of RS-RARP, particularly the improved early continence rates. Second, patients need to have a clear understanding of the potential drawbacks, including any possible impact on oncological safety or other long-term outcomes. Third, surgeons can explain how RS-RARP fits into the latest evidence and how it compares to alternative approaches, such as standard RARP. Finally, surgeons can assess individual factors such as cancer stage, overall health, and patient preferences to determine if RS-RARP is the most suitable option.